Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds like Tie me kangaroo downsport!
So we tanned his hide, and that it hanging on the shed!
Go NNVC
Love them VK landers!
What makes me doubt it but also wonder is the recent extension to the warrants. That would be sweet if someone could play that deal.
IN_COW_RESTING!
As was said, it is coming rather anonyomously from the same group that has someone say it was a house of cards. Why believe one and not the other. Hummmmm
ACE! NNVC has our friend in VK land
We have been working you blokes and sheilas on the 15 meter band and 10 meter band during recent sunspot activity!
Maybe NNVC will make us all Tall Poppies someday!
Take care from RFW!
HS
SK
I love the VK landers!
VK Landers love NNVC!
Well, now that is interesting!
If for real, too bad for longs as even a buyout at $50/share would be a rip-off to longs on a long term basis.
If not for real, it is the shorts like the Pump Terminator who covered and went long, just to short again based on a rumor pop.
Wierd days in the securities markets these days!
HS
Additionally, NNVC did the respectable thing.
They issued notice to Seeking Alpha, where upon they asked them to remove the libelous article from their site. Since Seeking Alpha refused, this action became required and Seeking Alpha is now fully complict.
If Seeking Alpha has any integrity and/or any desire to better their position, they should remove the article immediately. If by some extraordinary chain of events the article is vindicated, it could be reinstated then.
It is Appropriate to put forth Legal Notice!
While it is legitimate to call NNVC’s actions a distraction of sorts, one must also understand that legal actions are separate, take minimal time from the principal clinical investigators at NNVC, and are required to be done.
These actions are required because if not, others use NNVC inaction as in indication of guilt and/or the hiding of improprieties.
It is a sad aspect of our society that in our legal system, if one does not within a reasonable period of time officially protest being libeled, then that then becomes circumstantial evidence against them that no said libelous action has taken place.
Pump terminator, facilitated through Seeking Alpha’s willing portal and support, also made indication that similar action would continue. NNVC is therefore forced to respond forcefully and officially as a matter of record in a timely manner, pure and simple.
I also agree with the postulate made by an earlier post that this action, as it brings forth more avenues for discovery, shows a confidence by NNVC management of their position and the lack of intent to perform harm with any such questioned past actions.
While unfortunate to be necessary, these actions improve NNVC’s standing.
It has already been done. No need for me to repeat it. Reference historical posts of those with more brains than I and let NNVC provide such to the courts on their own.
I love it. Thanks I needed a little levity this morning!
God bless you!
Are you down their in VK land?
You are correct, no problem at all.
The evidence for that is pretty obvious.
The old saying, you can't scream fire in a theater and claim the rights of the 1st.
Good for NNVC!
I am sick of people and groups acting like their actions champion them as protectors of freedom and the exposing of wrongdoing, when they themselves with their actions lead to the same or even worse. It is very tiring to see pompous little people like Pump Terminator or the leaders of groups like Seeking the lowest form of life (Alpha) always getting their way under a façade of being the ‘good guy’. Go NNVC, defend yourself. Start a class action suit against SA and all its damaging bull it has help to spew along the country side!
Why Invest in Nanoviricides Inc?
First and foremost, everyone must do their own due diligence! This is very important and universal! Investing in any company, especially a developmental stage company contains risk that only the individual considering it can ultimately assess their tolerance for.
Some investors simply like to follow smart money. While this approach is not always successful, it can have positive outcomes. Vanguard, one of the most well known for good solid investing, is considered by some to be part of the assemblage of ‘smart money’. Vanguard has bought and is holding NNVC. So has the ‘smart money’ house of Europe, Deutsche Bank, as well as many others.
What does NNVC offer? What makes it compelling to own?
The Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, when asked why he invested a total of $7 Million in the Company during the 2013 calendar year explained it this way; “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing”.
NNVC therapeutic efficacy tests indeed have shown remarkable results. Standardized test protocols with mice specially developed by those in the medical research community to have human susceptibility traits were injected with 1000x viral loads required to ensure death. These standard protocols then measure efficacy by recording the time it takes to die for a treated animal versus the control animal. Even a few hours of delayed death can be quite meaningful. For NNVC, and unprecedentedly, large percentages actually survived! That is extraordinary efficacy!
The NNVC therapeutics also show similar comparable efficacy for both the injectable and oral forms.
To date, the NNVC therapeutics used in both forms show no apparent toxicity issues. Specific detailed testing being currently planned and prepared for to verify. This is one of the final activities prior to starting planned tests in humans under FDA protocols. A new facility is in final stages of construction to allow production of the quantities of the drug candidates needed for those human trials.
Don’t understand the technology? Could it be too good to be true? For further study, information about NNVC’s novel, proprietary anti-virus platform technology was published in a book by one of the world leading scientific reference publication houses; the CRC Press Publications. The book entitled Bionanotechnology II: Global Prospects, provides an in-depth presentation of the NanoViricides platform technology, evidence for how nanoviricides are believed to act plus dramatic results of nanoviricides specifically targeting certain viral diseases, such as HIV and the ocular disease, epidemic keratoconjunctivitis (EKC). Please reference the link below for further information in that regard;
http://books.google.com/books?id=K_Wy4Fq-QcMC&pg=PA141&lpg=PA141&dq=Bionanotechnology+II:+Global+Prospects+Nanoviricides+-+A+Novel+Approach+to+Antiviral+Therapeutics&source=bl&ots=XWUh8uwFPy&sig=CxX9RQd5RgDhksPyNYl_1dw0lh0&hl=en&sa=X&ei=-50SU5XlEMWkyAHil4DIDQ&ved=0CCcQ6AEwAg#v=onepage&q=Bionanotechnology%20II%3A%20Global%20Prospects%20Nanoviricides%20-%20A%20Novel%20Approach%20to%20Antiviral%20Therapeutics&f=false
NNVC’s work is far enough along and superior enough that it was awarded an orphan drug development designation in both the United States and in Europe! Even the Aussies have interest!
The FDA orphan designation also means NNVC is now has the potential to receive a FDA Priority Review Voucher (PRV). PRVs are transferable and can be worth upwards of one-half Billon Dollars or more in the pharmaceutical development market place!
Dr. Eva Harris, Professor of infectious diseases at UC Berekeley, president of the Sustainable Sciences Institute., a well renowned medical researcher whose papers and studies into the pathogenesis and epidemiology of infectious diseases have been of benefit to the medical community for years has performed independent efficacy studies of NNVC’s anti-viral candidate for Dengue Fever. Dr. Harris’s testing indicated a very high level in the efficacy of the Nanoviricide against the Denque fever virus in lethal animal models specially designed to yield highly controlled and applicable studies and data. Her work provides a strong independent confirmation that NNVC science has validity and high potential.
General investing principles often use insider buys as an indication of insider confidence. A major NNVC insider has indeed purchased more shares from the open market in recent weeks. Typically this is considered a very positive sign.
A uniquely valuable aspect of NNVC therapeutics are that they appear to be of a programmable or modifiable design that can potentially target nearly any type of virus in a very short time, potentially in a matter of weeks. This is very important considering that it is not if, but when, the next major pandemic hits the world.
As compared to oseltamivir, results demonstrated that oral administration of two different NNVC FluCide drug candidates produced significantly greater reduction in viral loads!
NNVC’s lead anti-HIV candidate also achieved a long term anti-HIV effect with a much shorter dosing regimen and a markedly lower total drug dose than that of the HAART Drug Cocktail therapy. Treatment with the lead anti-HIV nanoviricide reduced HIV levels and protected the human T cells (CD4+,CD8+) to the same extent as treatment with the HAART cocktail in the SCID/hu Thy/Liv mouse model.
In addition to other patents surrounding NNVC’s proprietary technologies, NNVC’s chairman and president Anil Diwan, et.al., received US Patent (No. 8,173,764) for "Solubilization and Targeted Delivery of Drugs with Self-Assembling Amphiphilic Polymers." The patent term is expected to last through October 1, 2026, including an anticipated extension, with the possibility of further extensions in compensation for time spent in clinical trials.
NNVC is also working with the very reputable Viroclinics Biosciences in the Netherlands to test various Nanoviricdes as therapeutics for a range of emerging world viral threats.
Are there any negatives? There typically is always something of at least some concern. Currently the following come to mind;
While NNVC’s product efficacy tests and evaluations have shown excellent results, their mover toward human clinical trials will undoubtedly incur a greater expenditure. While the company has indicated it has sufficient funding to make it to the human trials, any delays might produce a need for additional funds.
Additionally, there is a current legal matter which appears to be not settled in its entirety. While from a developmental company funding standpoint and from an industry comparative and historical perspective, NNVC stock dilution has been minimal suggesting good stewardship of funding by providing high achievement results per unit dollar invested, there is some questions brought about by the legal actions as to possible conflicts of interests. Of note is that the plaintiff indicates a desire to not be a significant hostile threat to the company and has made clear that the intent of actions is primarily to improve corporate governance, and that as an investor in the company, believes in its prospects and desire NNVC it to ultimately succeed. How any such resulting court actions might unfold is uncertain at this time. This type of issue is not uncommon with scientific based start-ups where the principals desire strong control over their inventions and might not be as astute to all issues surrounding corporate governance, especially as the company’s activities expand with growth and success in the product development. No company perfectly executes its growth path. So far though, NNVC does appear to have managed their funds effectively to produce a potential game changing anti-viral therapeutic product in a relatively short period of time with a reasonable expenditure. For that they should be commended.
Above all, remember, do your own DD. Don’t blindly follow. Know your risk level. Beware of misinformation, whether it be intentional or not.
Read, study, think; it is a process that behooves us all.
Disclosure; The writer of this post maintains an equity position in NNVC common stock. While the writer has science and engineering R&D experience, it is not specifically within the medical or pharmaceutical field. Nor does the writer have formal equity research training. The above information is generally available through official documents and new releases. It is the writer’s personal opinion that the science behind NNVC’s technology and the efficacies reported to date are valid and present and opportunity to advance medical therapeutics in the anti-viral arena significantly.
While I have appreciated some of your opinions, if you think you might get burned--->Dont bother investing in NNVC, or unfortunately in many other companies. I have been burned by some that were considered by far and away some of the safest. This remains a speculative developmental stage biotech company. Taking risk and putting up with all the c ra p that gets spewn about is par for the course. If you really dont want to participate simply dont. Everything, even waking up in the morning has risks.
A correction is in order, it has been brought to my attention that patent I referenced in the post was issued to Anil Diwan, et.al., not NNVC specifically. I apologize for any level of misinformation I might have propagated.
Why consider investing in NNVC?
First and foremost, everyone must do their own due diligence! This is very important and universal!
Some investors simply like to follow smart money. While this approach is not always successful, it can have positive outcomes. Vanguard, one of the most well known for good solid investing, is considered by some to be part of the assemblage of ‘smart money’. Vanguard has bought and is holding NNVC. So has the ‘smart money’ house of Europe, Deutsche Bank, as well as many others.
What does NNVC offer? What makes it compelling to own?
The Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, when asked why he invested a total of $7 Million in the Company during the 2013 calendar year explained it this way; “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing”.
NNVC therapeutic efficacy tests indeed have shown remarkable results. Standardized test protocols with mice specially developed by those in the medical research community to have human susceptibility traits were injected with 1000x viral loads required to ensure death. These standard protocols then measure efficacy by recording the time it takes to die for a treated animal versus the control animal. Even a few hours of delayed death can be quite meaningful. For NNVC, and unprecedentedly, large percentages actually survived! That is extraordinary efficacy!
The NNVC therapeutics also show similar comparable efficacy for both the injectable and oral forms.
To date, the NNVC therapeutics used in both forms show no apparent toxicity issues. Specific detailed testing being currently planned and prepared for to verify. This is one of the final activities prior to starting planned tests in humans under FDA protocols. A new facility is in final stages of construction to allow production of the quantities of the drug candidates needed for those human trials.
Don’t understand the technology? Could it be too good to be true? For further study, information about NNVC’s novel, proprietary anti-virus platform technology was published in a book by one of the world leading scientific reference publication houses; the CRC Press Publications. The book entitled Bionanotechnology II: Global Prospects, provides an in-depth presentation of the NanoViricides platform technology, evidence for how nanoviricides are believed to act plus dramatic results of nanoviricides specifically targeting certain viral diseases, such as HIV and the ocular disease, epidemic keratoconjunctivitis (EKC). Please reference the link below for further information in that regard;
http://books.google.com/books?id=K_Wy4Fq-QcMC&pg=PA141&lpg=PA141&dq=Bionanotechnology+II:+Global+Prospects+Nanoviricides+-+A+Novel+Approach+to+Antiviral+Therapeutics&source=bl&ots=XWUh8uwFPy&sig=CxX9RQd5RgDhksPyNYl_1dw0lh0&hl=en&sa=X&ei=-50SU5XlEMWkyAHil4DIDQ&ved=0CCcQ6AEwAg#v=onepage&q=Bionanotechnology%20II%3A%20Global%20Prospects%20Nanoviricides%20-%20A%20Novel%20Approach%20to%20Antiviral%20Therapeutics&f=false
NNVC’s work is far enough along and superior enough that it was awarded an orphan drug development designation in both the United States and in Europe! Even the Aussies have interest!
The FDA orphan designation also means NNVC is now eligible for a FDA Priority Review Voucher (PRV). PRVs are transferable and can be worth upwards of one-half Billon Dollars or more in the pharmaceutical development market place! What a sudden shot in the arm that would be! It is almost like a hugely positive Wild Card hanging out there!
Dr. Eva Harris, Professor of infectious diseases at UC Berkeley, president of the Sustainable Sciences Institute., a well renowned medical researcher whose papers and studies into the pathogenesis and epidemiology of infectious diseases have been of benefit to the medical community for years has performed independent efficacy studies of NNVC’s anti-viral candidate for Dengue Fever. Dr. Harris’s testing indicated a very high level in the efficacy of the Nanoviricide against the Denque fever virus in lethal animal models specially designed to yield highly controlled and applicable studies and data. Her work provides a strong independent confirmation that NNVC science has validity and high potential.
General investing principles often use insider buys as an indication of insider confidence. A major NNVC insider has indeed purchased more shares from the open market in recent weeks. Typically this is considered a very positive sign.
A uniquely valuable aspect of NNVC therapeutics are that they appear to be of a programmable or modifiable design that can potentially target nearly any type of virus in a very short time, potentially in a matter of weeks. This is very important considering that it is not if, but when, the next major pandemic hits the world.
As compared to oseltamivir, results demonstrated that oral administration of two different NNVC FluCide drug candidates produced significantly greater reduction in viral loads!
NNVC’s lead anti-HIV candidate also achieved a long term anti-HIV effect with a much shorter dosing regimen and a markedly lower total drug dose than that of the HAART Drug Cocktail therapy. Treatment with the lead anti-HIV nanoviricide reduced HIV levels and protected the human T cells (CD4+,CD8+) to the same extent as treatment with the HAART cocktail in the SCID/hu Thy/Liv mouse model.
In addition to other patents surrounding NNVC’s proprietary technologies, NNVC has also received US Patent (No. 8,173,764) for "Solubilization and Targeted Delivery of Drugs with Self-Assembling Amphiphilic Polymers." The patent term is expected to last through October 1, 2026, including an anticipated extension, with the possibility of further extensions in compensation for time spent in clinical trials.
NNVC is also working with the very reputable Viroclinics Biosciences in the Netherlands to test various Nanoviricdes as therapeutics for a range of emerging world viral threats.
Are there any negatives? There typically is always something of at least some concern. Currently the following come to mind;
While NNVC’s product efficacy tests and evaluations have shown excellent results, their move toward human clinical trials will undoubtedly incur a greater expenditure. While the company has indicated it has sufficient funding to make it to the human trials, any delays might produce a need for additional funds.
Additionally, there is a current legal matter which appears to be not settled in its entirety. While from a developmental company funding standpoint and from an industry comparative and historical perspective, NNVC stock dilution has been minimal suggesting good stewardship of funding by providing high achievement results per unit dollar invested, there is some questions brought about by the legal actions as to possible conflicts of interests. Of note is that the plaintiff indicates a desire to not a significant hostile threat to the company and has made clear that the intent of actions is primarily to improve corporate governance, and that as an investor in the company, believes in its prospects and desire NNVC it to ultimately succeed. How any such resulting court actions might unfold is uncertain at this time. This type of issue is not uncommon with scientific based start-ups where the principals desire strong control over their inventions and might not be as astute to all issues surrounding corporate governance, especially as the company’s activities expand with growth and success in the product development.
No company perfectly executes its growth path. So far though, NNVC does appear to have managed their funds effectively to produce a potential game changing anti-viral therapeutic product in a relatively short period of time with a reasonable expenditure. For that they should be commended.
Above all, remember, do your own DD. Don’t blindly follow. Know your risk level. Beware of misinformation, whether it be intentional or not.
Read, study, think; it is a process that behooves us all.
Wishing all the best of good buys!
HS
INVESTOR ALERT: The Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company was asked why he invested a total of Seven Million Dollars (7,000,000.00 USD) in the Company during the 2013 calendar year. In his own words, he explained it this way; “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing”.
Who am I to disagree with such a massively educated intelligent person!
Wishing all the best of good buys!
HS
INVESTOR ALERT: NanoViricides could corner on the market according to FierceDrugDelivery article!
http://www.fiercedrugdelivery.com/story/virus-killing-nanoviricides-win-orphan-status-dengue-fever/2013-08-14#ixzz2upOQEykY
Great article!
Quote - 'The recent addition of the company's DengueCide for dengue fever to the list of the FDA's orphan drugs could possibly give NanoViricides a corner on the market. The treatment showed an unprecedented 50% survival rate in animal trials. When left untreated, dengue fever has 100% fatality, and there are only a few drugs in the clinical stage, including balapiravir from Roche'
Read more: Virus-killing nanoviricides win orphan status for dengue fever - FierceDrugDelivery http://www.fiercedrugdelivery.com/story/virus-killing-nanoviricides-win-orphan-status-dengue-fever/2013-08-14#ixzz2upOQEykY
Throwing money at something is typically a bad idea in most cases. That is unless they are throwing it at me!
I would certainly not advise NNVC to secure more funds just to throw it at the wall or whatever. However, the pace of critical path stage gates can be enhanced in almost every single endeavor any company has in nearly any product development.
There is real and tangible danger in taking too many years to unfold a package.
I tend to agree, that is why I would actually be in favor of more dilution if it meant the funds could be efficiently applied to an accelerated process.
For those of you formally educated in the Sciences, the CRC Press Publications are quite familiar.
They published the first edition of the Handbook of Chemistry and Physics in 1913. Before long, the Handbook became the standard reference for chemists and physicists worldwide!
Shortly thereafter, they became the world leader in scientific reference publications and remain so to this date. To achieve that respected status, they have never participated in disseminating ‘snake oil’ science and technology.
They do a separate level of due diligence to ensure what they print has validity.
If for some reason the cruel world of business and malevolent equity manipulators prevent NNVC from reaching the heights they deserve, it won’t be because their trying to sell ‘snake oil’ as some of these types of groups and individuals have proposed in recent weeks.
NNVC News.....'Detailed lab analysis showed no overt adverse safety and toxicology effects from the company’s broad-spectrum anti-influenza candidate, even at the maximum feasible dose level. The results were consistent with the preliminary findings of the study.
Detailed analyses of samples from the study showed no overall system effects and no direct effects on the primary organs, including liver and kidney tissues. The results supported the company’s previous findings in animal studies that showed no safety or toxicology concerns.
NanoViricides previously reported that its FluCide candidate demonstrated very high anti-influenza activity in lethal infection animal models using multiple subtypes of influenza A. The high anti-influenza activity along with the positive safety data were the basis for selecting FluCide for further drug development.
The results of the study will provide the basis and focus for the GLP safety and toxicology studies of FluCide that are required for the investigational new drug submission to the U.S. Food and Drug Administration.'
CRC Press Publication for those who like to read about NNVC's outstanding technology:
http://books.google.com/books?id=K_Wy4Fq-QcMC&pg=PA141&lpg=PA141&dq=Bionanotechnology+II:+Global+Prospects+Nanoviricides+-+A+Novel+Approach+to+Antiviral+Therapeutics&source=bl&ots=XWUh8uwFPy&sig=CxX9RQd5RgDhksPyNYl_1dw0lh0&hl=en&sa=X&ei=-50SU5XlEMWkyAHil4DIDQ&ved=0CCcQ6AEwAg#v=onepage&q=Bionanotechnology%20II%3A%20Global%20Prospects%20Nanoviricides%20-%20A%20Novel%20Approach%20to%20Antiviral%20Therapeutics&f=false
Why does the Bank Of New York, one of the most trusted caretakers of wealth in the nation, think NNVC is worth owning now?
Ask them. Give them a call to find out. You might just find is has something to do with the facts. Facts like:
NNVC therapeutic efficacy testing show remarkable results. Standardized test protocols with mice specially developed by those in the medical research community to have human susceptibility traits injected with 1000x viral loads required to ensure death. Standard industry protocols that measure efficacy by the time it takes to die for a treated mouse versus the control mice. Unprecedentedly, large percentages actually survive! Almost unheard of efficacy!
NNVC therapeutics shown to have similar efficacy in both injectable and oral forms.
NNVC therapeutics used in both forms show no apparent toxicity issues to date. Specific testing being currently planned and prepared for to verify.
From a comparative and historical perspective, stock dilution has been minimal demonstrating good stewardship and results per unit dollar achievement.
NNVC’s work good enough that is was awarded an orphan drug development designation in both the United States and Europe.
NNVC work good enough to now be an official candidate for a FDA Priority Review Voucher.
NNVC science independently confirmed by independent researchers in the area of pathogenesis and epidemiology of infectious diseases.
NNVC currently has sufficient funds to support 2 years of operations and into first human trials.
NNVC major insider purchases more shares from the open market in recent weeks.
NNVC therapeutics appear to be of a programmable design that can target nearly any type of virus in a matter of weeks!
Oh, and that is just to name a few possible reasons.
In the not too distant future, it just might be an NNVC nanoviricide that saves your life, or the life of a loved one. Do your own DD. Beware of misinformation. Read, study, think; a process that behooves us all.
Wishing all the best of good buys!
HS
Cases in Florida, Texas and New York, in addition to 25,000 suspected cases reported in Puerto Rico this past summer, the Dengue virus is clearly becoming an important pathogen of concern in the United States.
NanoViricide's DengueCide™ drug candidate has been awarded orphan drug status by the U.S. Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA), covering the USA and all the 27 countries within the European Union. This drug candidate has shown unprecedented effectiveness in a special mouse model that simulates secondary dengue/dengue hemorrhagic fever.
And as a result, the innocent go on getting persecuted by those with money and agendas to bully and persecute them with and for.
I wonder why SA needs so many lawyers specializing in journalism liability? That is a big question that might be worth asking oneself when evaluating the validity of the article related to NNVC.
When the Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company was asked why he invested a total of Seven Million Dollars (7,000,000.00 USD) in the Company during the 2013 calendar year, he explained it this way; “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing”.
Well, he is a little more learned than I, who am I to disagree!
Wishing all the best of good buys!
HS
According to Official Company News Releases
NNVC has renewed a contract with independent researcher Dr. Eva Harris, a world expert in Dengue Fever and other infecteous diseases. Dr. Harris is reported to have an excellent mouse model of dengue virus infection and disease.
NNVC Company used this recognized expert in the world to evaluate its anti-dengue agents. In those studies, the their treatment produced a high level of effectiveness. In Prof. Harris’ model of dengue vascular leak, dengue virus infection of the laboratory mouse strain, AG129, is 100% fatal when the mice are untreated. In contrast, in the same study, animals treated with one of NanoViricides' anti-dengue agents achieved an unprecedented 50% survival rate!
I anticipate extended studies will further demonstrate DengueCide effectiveness in the treatment of Dengue Fever.
Warning - Investors should beware of misinformation and suggestive issues associated with various links presented here.
Investors in NNVC should do their own due diligence and decide for themselves how to proceed.
Best of luck to all honest investors attempting to weed through the good information from the misleading.
Viroclinics Biosciences, a spinoff of the Department of Viroscience at the Erasmus Medical Centre in the Netherlands has a confidentiality agreement to will allow their scientists to develop the testing of different nanoviricides for multiple viruses of mutual interest to both organizations.
Just another set of independent researchers dedicated to saving millions, if not billions of lives, highly interested in NNVC technology.
You appear to be just a person trying to be a good investor by not totally discounting what can come of things, ligitimate or not.
I appreciate your candor and approach. It is certainly posible that NNVC has not been perfect at executing its business and developmental iniciatives. However is sincerely doubt anything they may have done was nefarious in any way. Do they want to protect their interests, I would think so. Are they a group of honest doctors trying to save lives, I also think that is true. Are they out there to steal from investors, I think not. Is it possible they may have headwinds due to possible misteps and/or mistakes...well of course.
Overall though, you simply appear to be a very cautious investor. The fact that such a cautious investor is considering the merits of NNVC, I see as a plus.
Welcome aboard. All thoughtfull comments that are made without malice or without manipulative motives are always welcome!
Good luck with all your research and investing. Even the best most clean cases can get trampled on. Good DD in not always rewarded.
Best of luck
HS
NNVC major insider has purchased more shares from the open market in recent weeks. Typically this is considered a very positive sign.
You are probably right. It is both a shame and a classic that the good get taken advantage of and the bad get away with all sorts of bad behaviours, slanders and violations.
NNVC is not the only company to be falsely attacked for personal gain and have the purpitrators get away with it, and it wont be the last.
Reduce CO2, Create Jobs, use American Energy by builing a select set of new coal fired ultra supercritical boilers to replace a select group of older lesser efficient units. Result is more jobs, use of American reserves for America, strengthens the US strategic energy structure, builds a real bridge to the future and puts forth less pollutants and CO2 into the atmosphere for a given unit energy delivered to the public.
In Prof. Harris’ model of dengue vascular leak, dengue virus infection of the laboratory mouse strain, AG129, is 100% fatal when the mice are untreated. In contrast, in the same study, animals treated with one of NanoViricides' anti-dengue agents achieved an unprecedented 50% survival rate.
Is the Great Bank of New York Mellon on to something?
Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company has invested a total of $7 Million in the Company during the 2013 calendar year. When asked why he has made these investments, he explained that “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing”.
Why does Vanguard, one of the most well known for good solid investing, think NNVC is worth now holding as they do?
Well it just could be that;
NNVC therapeutic efficacy testing show remarkable results. Standardized test protocols with mice specially developed by those in the medical research community to have human susceptibility traits injected with 1000x viral loads required to ensure death. Standard industry protocols that measure efficacy by the time it takes to die for a treated mouse versus the control mice. Unprecedentedly, large percentages actually survive! Almost unheard of efficacy!
NNVC therapeutics shown to have similar efficacy in both injectable and oral forms.
NNVC therapeutics used in both forms show no apparent toxicity issues to date. Specific testing being currently planned and prepared for to verify.
From a comparative and historical perspective, stock dilution has been minimal demonstrating good stewardship and results per unit dollar achievement.
NNVC’s work good enough that is was awarded an orphan drug development designation in both the United States and Europe.
NNVC work good enough to now be an official candidate for a FDA Priority Review Voucher.
NNVC science independently confirmed by independent researchers in the area of pathogenesis and epidemiology of infectious diseases.
NNVC currently has sufficient funds to support 2 years of operations and into first human trials.
NNVC major insider purchases more shares from the open market in recent weeks.
NNVC therapeutics appear to be of a programmable design that can target nearly any type of virus in a matter of weeks!
Oh, and that is just to name a few possible reasons.
In the not too distant future, it just might be an NNVC nanoviricide that saves your life, or the life of a loved one. Do your own DD. Beware of misinformation. Read, study, think; a process that behooves us all.
Wishing all the best of good buys!
HS
Spartan Extended Market Index Fund BUYs NNVC shares!
and maintains a position for their mutual fund!
And thats no shit! I never have quite understood why someone would get on one of those ships. I know clinical microbioligists in Miami clinical labs that report significant amounts of nasty bugs on these vessels and associated with the crews. Floating sewers with mint frosting!